The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

Inclusion Criteria Concurrent Medication: Required: Stable prescribed dosage of zidovudine (AZT), = or > 500 mg/day. Allowed: Prophylaxis for Pneumocystis carinii pneumonia (PCP) with aerosolized pentamidine. Erythropoietin. Patients must be: HIV positive by ELISA and Western blot. Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day. Significant underlying medical condition that could impair continuous participation in study. Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight). Concurrent Medication: Excluded: Oral contraceptives. Cytotoxic chemotherapy. Ganciclovir. Flucytosine. Probenecid. Opiates. Valproic acid. Sulfa drugs. Sucralfate. Dapsone. Rifampin. Antacids within 2 hours of zidovudine (AZT) dose. Isoniazid. Ketoconazole. Pyrimethamine. Clindamycin. Aspirin. Ibuprofen. Investigational drugs not specifically allowed. Patients with the following are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day. Significant underlying medical condition that could impair continuous participation in study. Unable to take oral medication reliably. Prior Medication: Excluded within 30 days of study entry: Antiretroviral agents other than zidovudine (AZT).